Caris Life Sciences and Everlywell Join Forces for Revolutionary Cancer Detection Technology

Innovative Partnership to Transform Cancer Detection

In a significant advancement for cancer screening, Caris Life Sciences has announced a partnership with Everlywell, a digital health company. This collaboration aims to introduce Caris Detect™, an innovative Multi-Cancer Early Detection (MCED) assay designed to identify multiple cancer types through a blood sample. The technology leverages comprehensive whole genome sequencing (WGS) methods to analyze molecular signals present in the bloodstream, making early detection of cancer possible.

Caris Life Sciences, a leader in precision medicine and AI-driven healthcare solutions, plans to launch Caris Detect in the first half of 2026. According to David Spetzler, President of Caris, this collaboration is a major step towards enhancing access to revolutionary cancer screening technologies, ultimately positioning patients for better outcomes. He noted, "By combining our leading-edge precision medicine technologies with Everlywell's established consumer-focused approach, we are paving the way for earlier and more effective cancer detection."

Caris Detect is expected to reshape how cancers are identified at the earliest stages — when they are most treatable. This partnership is particularly noteworthy, as it capitalizes on Everlywell’s expertise in health diagnostics, ensuring that health insights are not only accurate but also accessible. Julia Cheek, the CEO of Everlywell, emphasized the importance of this partnership, stating that it represents a significant leap in proactive cancer detection methods.

A New Era of Cancer Screening

The traditional methods of cancer detection often lead to diagnoses at advanced stages, where treatment options may be limited. Caris Detect aims to change that by providing a blood test that can screen for various cancer types, offering patients a proactive approach to their health. This capability is set to empower individuals with knowledge about their health, enabling them to take timely actions in consultation with healthcare providers.

Through integration with Everlywell's user-friendly platform, patients will receive their testing kits and have easy access to their results, streamlining the entire testing process. This innovative service strengthens the trend towards personalized healthcare, where patient involvement and informed decisions are critical.

About Caris Life Sciences and Everlywell

Caris Life Sciences is a recognized pioneer in precision medicine, utilizing artificial intelligence and advanced molecular profiling to transform healthcare. Their technologies allow for a deep analysis of diseases, leading to personalized treatment options that can improve patient outcomes.

Everlywell, on the other hand, has spent the past decade setting industry standards for accessible diagnostics. With its AI-powered technology combined with human insight, Everlywell delivers personalized health answers and aims to change how health assessments are conducted by closing care gaps and enhancing the patient experience.

With this partnership, both companies aim to unlock a new chapter in healthcare, rethinking how cancer is detected and managed. Together they present a united front in the fight against cancer, promising to facilitate earlier detection and more personalized treatment pathways that could significantly enhance patient management.

The approach taken by Caris Life Sciences and Everlywell exemplifies the future of healthcare: a fusion of technology, insight, and personal health management that places the patient's needs at the forefront of medical innovations. As they gear up for the product launch of Caris Detect, the anticipation in the healthcare community is palpable, potentially marking a pivotal moment in cancer detection and treatment strategies.